Faricimab for hard-to-treat wet age-related macular degeneration
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests a new injection called faricimab for people with wet age-related macular degeneration (AMD) that hasn't improved enough with standard anti-VEGF shots. The goal is to see if faricimab can reduce retinal fluid and improve vision in patients who still have fluid despite many previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 80 years old.
- You have been diagnosed with wet age-related macular degeneration (a condition causing fluid buildup under the retina).
- You have already received at least 6 anti-VEGF injections in the last year (or at least 4 in the last 6 months) and still have fluid in your retina.
- Your vision is between about 20/40 and 20/320 (you can read some letters on an eye chart).
- You do not have other major eye diseases or uncontrolled health conditions like high blood pressure or diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study observes how a drug called faricimab works in treating wet AMD (a condition affecting central vision in older adults). You would receive four initial injections into your eye, then additional injections as needed based on your response.
This study tests a combination of standard eye injections and laser treatment for wet age-related macular degeneration, a condition where abnormal blood vessels leak fluid and harm vision. It aims to see if this combined approach is safe and effective, potentially reducing the number of injections needed.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
This study tests if faricimab, an injectable eye medication, can improve vision in people with a newly diagnosed form of wet age-related macular degeneration (AMD). It is for patients who have not yet received treatment for this condition.
This trial tests a new drug called Faricimab for people with a specific type of wet age-related macular degeneration (AMD) that has a buildup of material beneath the retina. The goal is to see if Faricimab can help clear this material and improve vision.
This trial tests if faricimab eye injections given every 3 months can keep wet age-related macular degeneration under control. It is for people with a new or returning active blood vessel growth in the center of the macula.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.